{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses the role of a-synuclein in neuronal plasticity and neurodegenerative disease, specifically Parkinson's disease (PD), and its function in inhibiting phospholipase D (PLD).",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay, which is the inhibition of PLD by a-synuclein and its implications in PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses in vitro PLD2 inhibition assays to evaluate the functional impact of a-synuclein variants, including A30P.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (PLD inhibition) effectively models the disease mechanism defined in Step 1, as PLD inhibition is implicated in synaptic vesicle recycling and PD pathology.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper describes the use of wild-type and mutant synuclein proteins, including controls and multiple replicates, in PLD2 inhibition assays.",
          "judgment": "Yes",
          "reasoning": "Basic controls (wild-type and mutant proteins) and replicates were used, indicating a valid assay setup.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compares the A30P mutant to wild-type a-synuclein and other mutants in PLD2 inhibition assays.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic and benign variants were used as controls, and the A30P mutant was compared to these.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The A30P mutant did not differ significantly from wild-type in its capacity to inhibit PLD2, suggesting it does not have a pathogenic effect in this context.",
          "judgment": "No",
          "reasoning": "The A30P mutant's functional impact was similar to wild-type, indicating no pathogenic effect in the PLD2 inhibition assay.",
          "next_step_or_outcome": "Do not use PS3/BS3"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "N/A"
      },
      "overall_conclusion": "The A30P variant does not show a pathogenic effect in the PLD2 inhibition assay, suggesting it does not contribute to PD through this mechanism."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses the role of a-synuclein in neuronal plasticity and neurodegenerative disease, specifically Parkinson's disease (PD), and its function in inhibiting phospholipase D (PLD).",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay, which is the inhibition of PLD by a-synuclein and its implications in PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses in vitro PLD2 inhibition assays to evaluate the functional impact of a-synuclein variants, including A53T.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (PLD inhibition) effectively models the disease mechanism defined in Step 1, as PLD inhibition is implicated in synaptic vesicle recycling and PD pathology.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper describes the use of wild-type and mutant synuclein proteins, including controls and multiple replicates, in PLD2 inhibition assays.",
          "judgment": "Yes",
          "reasoning": "Basic controls (wild-type and mutant proteins) and replicates were used, indicating a valid assay setup.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compares the A53T mutant to wild-type a-synuclein and other mutants in PLD2 inhibition assays.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic and benign variants were used as controls, and the A53T mutant was compared to these.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The A53T mutant displayed enhanced inhibition of PLD2 as compared to wild-type hAS, suggesting a gain-of-function effect.",
          "judgment": "Yes",
          "reasoning": "The A53T mutant's enhanced PLD2 inhibition suggests a pathogenic gain-of-function, consistent with its association with autosomal dominant PD.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not provide statistical analyses sufficient to calculate OddsPath for the A53T variant's functional data.",
          "judgment": "No",
          "reasoning": "Without OddsPath calculation, we proceed to evaluate the number of variant controls used in the study.",
          "next_step_or_outcome": "Proceed to count variant controls"
        },
        {
          "step_name": "Count Variant Controls",
          "extracted_paper_info": "The study uses multiple variants as controls, including wild-type, A30P, and other mutants, totaling at least 11 variants.",
          "judgment": "Yes",
          "reasoning": "With at least 11 variant controls used across the study, the functional evidence strength is moderate.",
          "next_step_or_outcome": "Assign moderate strength"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The A53T variant shows enhanced PLD2 inhibition, suggesting a pathogenic gain-of-function effect, supported by moderate functional evidence strength due to the use of multiple variant controls."
    }
  ]
}